Tag Archives: first-line chemotherapy

COIN: No Benefit Found Adding Cetuximab to FOLFOX or CAPOX in First-Line CRC Treatment

Even in colorectal cancer patients with wild-type KRAS mutations, there was no increase in overall survival time or in the time it took before cancer progressed when Erbitux® (cetuximab) was added to FOLFOX or CAPOX chemotherapy. More tumors got smaller with Erbitux treatment, but there was an increase in both serious gastrointestinal toxicity and severe skin rash when the drug was added. Patients with tumor mutations in any of three genes — KRAS, BRAF, or NRAS — had poorer survival.

Top